JUNO THERAPEUTICS INC (JUNO) Stock Price, Quote, News and Overview
NASDAQ:JUNO - Nasdaq - US48205A1097
JUNO Quote, Performance and Key Statistics
NASDAQ:JUNO (3/5/2018, 8:38:56 PM)
86.96
+0.09 (+0.1%)
The current stock price of JUNO is 86.96 null. In the past month the price increased by 1.59%. In the past year, price increased by 286.83%.
About JUNO
Company Profile
Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms - Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.
Company Info
JUNO THERAPEUTICS INC
400 DEXTER AVENUE NORTH SUITE 1200
SEATTLE WA 98109
CEO: Hans E. Bishop
Phone: 206-582-1600
JUNO THERAPEUTICS INC / JUNO FAQ
What is the stock price of JUNO THERAPEUTICS INC today?
The current stock price of JUNO is 86.96 null. The price increased by 0.1% in the last trading session.
What is the ticker symbol for JUNO THERAPEUTICS INC stock?
The exchange symbol of JUNO THERAPEUTICS INC is JUNO and it is listed on the Nasdaq exchange.
On which exchange is JUNO stock listed?
JUNO stock is listed on the Nasdaq exchange.
What is JUNO THERAPEUTICS INC worth?
JUNO THERAPEUTICS INC (JUNO) has a market capitalization of 10.10B null. This makes JUNO a Large Cap stock.
What are the support and resistance levels for JUNO THERAPEUTICS INC (JUNO) stock?
JUNO THERAPEUTICS INC (JUNO) has a support level at 86.53 and a resistance level at 86.97. Check the full technical report for a detailed analysis of JUNO support and resistance levels.
Should I buy JUNO THERAPEUTICS INC (JUNO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of JUNO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of JUNO, evaluating the profitability, health, valuation and growth aspects
- JUNO THERAPEUTICS INC (JUNO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- JUNO THERAPEUTICS INC (JUNO) Sales and EPS estimates to see what analysts future expectations are.
- JUNO THERAPEUTICS INC (JUNO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- JUNO THERAPEUTICS INC (JUNO) Insider and Institutional Ownership to learn about the owners and their transactions.
- JUNO THERAPEUTICS INC (JUNO) Stock Chart to make your own analysis
- JUNO THERAPEUTICS INC (JUNO) Latest news and press-releases to stay up to date.
Does JUNO THERAPEUTICS INC (JUNO) stock pay dividends?
JUNO does not pay a dividend.
What is the Price/Earnings (PE) ratio of JUNO THERAPEUTICS INC (JUNO)?
JUNO THERAPEUTICS INC (JUNO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.1).
JUNO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to JUNO. When comparing the yearly performance of all stocks, JUNO is one of the better performing stocks in the market, outperforming 99.03% of all stocks.
JUNO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to JUNO. The financial health of JUNO is average, but there are quite some concerns on its profitability.
JUNO Financial Highlights
Over the last trailing twelve months JUNO reported a non-GAAP Earnings per Share(EPS) of -4.0972. The EPS decreased by -69.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -390.72% | ||
| ROA | -30.46% | ||
| ROE | -41.75% | ||
| Debt/Equity | 0.01 |